Cannabinoids and OCD: Promising Biology

Could the body’s endocannabinoid system help explain obsessive-compulsive disorder—and eventually lead to new treatments? Research has raised that possibility, but the evidence remains preliminary and does not yet support cannabis or cannabinoid medicines as established treatments for OCD.

A 2019 review in Cannabis and Cannabinoid Research, “The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder?”, examined findings from animal research, laboratory studies in people, and a small number of clinical reports. The authors focused on whether the endocannabinoid system, or ECS, might influence anxiety, fear learning, repetitive behavior, and the balance between habitual and goal-directed actions—processes relevant to OCD.

The ECS is a signaling network involved in regulating mood, stress responses, learning, and behavior. Cannabinoid type 1 receptors, known as CB1 receptors, are found in several brain regions involved in OCD-related circuitry, including parts of the prefrontal cortex, amygdala, and striatum. This biological overlap has prompted researchers to investigate whether altering ECS activity could affect obsessive-compulsive symptoms.

In animal models, increasing CB1 receptor activity or altering enzymes that break down endocannabinoids sometimes reduced anxiety-like and compulsive or repetitive behaviors. Other experiments suggested that ECS activity may help animals adapt to stress and extinguish learned fear responses. However, results from animal models cannot establish that a treatment will work in people with OCD, and the effects may depend heavily on the compound, dose, timing, and experimental model.

The human evidence available to the authors was much thinner. Studies involving dronabinol—a pharmaceutical form of THC—and cannabidiol, or CBD, had examined anxiety and fear learning primarily in healthy participants rather than people diagnosed with OCD. Research involving Tourette syndrome also offered indirect clues because the condition can involve obsessive-compulsive behaviors, but those studies were small and did not directly demonstrate that cannabinoids treat OCD.

At the time of the 2019 review, only three case reports directly described cannabinoid treatment in people with OCD. The patients had not responded adequately to conventional treatment and received dronabinol, generally as an addition to existing medication. Reported Yale-Brown Obsessive Compulsive Scale scores improved within roughly 10 days to two weeks in the cases described. These reports are notable signals for further research, but case reports have no control group and cannot distinguish a drug effect from placebo effects, changes in other treatments, fluctuating symptoms, or reporting bias.

Subsequent research has added only limited evidence. A small 2020 pilot study, testing the synthetic cannabinoid nabilone with exposure-based psychotherapy, included 11 unmedicated adults with OCD. Nabilone alone produced little symptom change, while the combination with exposure therapy showed greater improvement; several participants nevertheless withdrew, including some because of increased anxiety. Another human laboratory study examined the short-term effects of cannabinoids in adults with OCD, but acute laboratory findings are not the same as evidence of a safe and effective long-term treatment.

A 2026 scoping review provides a useful update: it identified just 13 eligible studies on the ECS and OCD, 12 of them preclinical and only one involving both animal and human samples. The review found broadly consistent signals in animal research that enhancing ECS activity can reduce compulsive or habitual behaviors, while inhibiting it can worsen them. It also concluded that clinical research is still needed before the findings can be translated into routine care. The full scoping review is available through PubMed.

For now, cannabinoids should be viewed as an experimental research avenue rather than an alternative to established OCD care. The National Institute of Mental Health identifies psychotherapy—particularly cognitive behavioral therapy with exposure and response prevention—and medication as the main evidence-based treatment approaches. Anyone considering cannabis, THC, CBD, dronabinol, or nabilone for OCD should discuss the risks and possible interactions with a qualified health professional rather than attempting to self-treat.